Firms join in new IMI adaptive pathways project
This article was originally published in Scrip
Executive Summary
The EU's Innovative Medicines Initiative (IMI) is about to launch a new collaborative public-private project looking at how best to co-ordinate and support activities being conducted in the area of adaptive pathways, with a view to producing a comprehensive plan for developing and using relevant tools and methodologies throughout the product life cycle.